Abortion pill access jumps almost 50% after Australia eases pharmacy restrictions

The number of Australian pharmacies stocking the abortion medication MS-2 Step increased by almost 50% after prescribing restrictions were relaxed, according to a study published in the medical journal JAMA Network Open. Researchers found that the number of pharmacies carrying the drug rose from 2,228 to 4,107 following changes introduced by the Therapeutic Goods Administration in 2023.

What changed in 2023

The 2023 reform allowed any general practitioner, rather than only specially accredited doctors, to prescribe MS-2 Step, the medication used for early medical abortion in Australia. The loosened rules were designed to widen access to the treatment beyond practitioners who had previously needed additional certification to prescribe it.

The study examined pharmacy stocking data before and after the change took effect, concluding that deregulation was associated with a substantial rise in the availability of the medication across the country. According to the researchers, the increase in pharmacies carrying the drug suggests that easing prescribing restrictions can translate directly into broader practical access for patients.

Implications for healthcare access

The authors of the study, reported by The Guardian, argue that the findings point to safer and faster healthcare outcomes when regulatory barriers around abortion medication are reduced. Wider pharmacy stocking means patients prescribed the medication are more likely to be able to fill that prescription without having to travel long distances or face delays.

The research adds to an ongoing international debate over how prescribing and dispensing rules shape real-world access to reproductive healthcare. In Australia, the 2023 changes to MS-2 Step prescribing have now been shown, through pharmacy stocking figures, to have had a measurable effect on availability nationwide.